Livedoid vasculitis
Livedoid vasculitis chirwere chisingaperi cheganda chinoonekwa zvakanyanya muvakadzi vechidiki kusvika pakati nepakati. Imwe acronym inoshandiswa kutsanangura maitiro ayo ndeye "Painful purpuric ulcers ine reticular pateni yezasi migumo" (PURPLE). Inobatanidzwa nehuwandu hwezvirwere, kusanganisira chisingaperi venous hypertension uye varicosities.
☆ Mune 2022 Stiftung Warentest mhedzisiro kubva kuGermany, kugutsikana kwevatengi neModelDerm kwakangodzikira zvishoma pane nekubhadharwa kwe telemedicine kubvunzana.
Inogona kuperekedzwa nemarwadzo.
References
Livedoid vasculopathy ichirwere cheganda chisingawanzoonekwa nemaronda anorwadza anoramba achidzoka kuzasi kwemakumbo.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy (LV) is a rare thrombotic vasculopathy of the dermis characterized by painful, relapsing ulcers over the lower extremities. Diagnosis is challenging due to the overlap in clinical appearance and nomenclature with other skin disorders. Treatment selection is complicated by poor understanding of the pathogenesis of LV and lack of robust clinical trials evaluating therapy efficacy. The terminology and pathophysiology of LV are reviewed here, along with its epidemiology, clinical and histologic features, and treatment options. A diagnostic pathway is suggested to guide providers in evaluating for comorbidities, referring to appropriate specialists, and choosing from the available classes of therapy.
Livedoid vasculopathy ichirwere cheganda chisingawanikwe chinokonzeresa maronda epazasi pemakumbo, zvichisiya mavanga akachenuruka anonzi atrophie blanche. Kunyange zvazvo chikonzero chaicho chisati chanyatsojeka, zvinotendwa kuti kuwedzera kweropa kugwamba (hypercoagulability) ndicho chinhu chikuru, nekuzvimba kunotora chikamu chechipiri. Zvinhu zvinokonzeresa kugwamba zvinosanganisira zvinotevera - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. Mune biopsies, mamiriro acho anoratidza kuvharika kweropa mukati memidziyo, kukora kwemadziro emidziyo, uye mavanga. Kurapa kunosanganisira nzira ine mativi akawanda yakatarisana nekudzivirira kugwamba kweropa nemishonga senge anti-platelet zvinodhaka, zvinoderedza ropa, uye fibrinolytic therapy. Mishonga yakasiyana-siyana inogona kushandiswa kune iyi mamiriro eganda - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy is a rare skin condition that causes recurring ulcers on the lower legs, leaving behind pale scars known as atrophie blanche. While the exact cause is still unclear, it's believed that increased blood clotting (hypercoagulability) is the main factor, with inflammation playing a secondary role. Factors contributing to clotting include as follows - deficiencies in proteins C and S, genetic mutations like factor V Leiden, antithrombin III deficiency, prothrombin gene mutations, high levels of homocysteine. In biopsies, the condition shows blood clots inside vessels, thickening of vessel walls, and scarring. Treatment involves a multi-pronged approach focusing on preventing blood clots with medications like anti-platelet drugs, blood thinners, and fibrinolytic therapy. Various drugs can be used for this skin condition - colchicine and hydroxychloroquine, vasodilators, immunosuppressants.
Livedoid vasculopathy inzvimbo isingawanzo kuitika apo maronda anoitika pamakumbo ese. Kuumbwa kweropa mutsinga duku dzeropa kunofungidzirwa kuti kunokonzerwa nekuwedzera kuvhara uye kuderedza kuparara kwevhavha, pamwe chete nekukuvara kwemudziyo wemidziyo. Inowanzoonekwa kuvakadzi, kunyanya pakati pemakore 15 ne50. Kurega kusvuta, kutarisira maronda, uye kushandisa mishonga yakaita seropa uye antiplatelet mishonga kwave kushanda.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
Livedoid vasculopathy is a rare vasculopathy that is typically characterized by bilateral lower limb lesions. Increased thrombotic activity and decreased fibrinolytic activity along with endothelial damage are believed to be the cause of thrombus formation in the capillary vasculature. It is 3 times more common in females than in males, especially in patients between the ages of 15 to 50 years. There is no definite first-line treatment, but general measures like smoking cessation, wound care, and pharmacological measures like anticoagulants and antiplatelets have shown good results.
